Evidence map›Paper›PMID 31771560›Full record

ArticleBMC pulmonary medicine2019

Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden.

Dimitrios Kalafatis, Jing Gao, Ida Pesonen, Lisa Carlson, C Magnus Sköld, Giovanni Ferrara

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020
    Pooled it
  3. Trial
  4. Prevalence and Prognostic Impact of Progressive Pulmonary Fibrosis.Tuberculosis and respiratory diseases · 2026
    Review
  5. Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dimitrios KalafatisRespiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Jing GaoRespiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Ida PesonenRespiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Lisa CarlsonRespiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
C Magnus SköldRespiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Giovanni FerraraRespiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Giovanni.Ferrara@ki.se.ORCID http://orcid.org/0000-0002-3807-3315

Funding

Hjärt-Lungfonden 20180660
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a disease with poor prognosis mainly affecting males. Differences in clinical presentation between genders may be important both for the diagnostic work-up and for follow-up. In the present study, we therefore explored potential gender differences at presentation in a Swedish cohort of IPF-patients.

methodsWe studied patients included in the Swedish IPF- registry over a three-year period from its launch in 2014. A cross-sectional analysis was performed for data concerning demographics, lung function, 6- min walking test (6MWT) and quality of life (QoL) (King's Brief Interstitial Lung Disease (K-BILD) score).

resultsThree hundred forty- eight patients (250 (72%) males, 98 (28%) females, median age 72 years in both genders) were included in the registry during the study period. Smoking history (N = 169 (68%) vs. N = 53 (54%), p < 0.05), baseline lung function (Forced vital capacity, % of predicted (FVC%): 68.9% ± 14.4 vs. 73.0% ± 17.7, p < 0.05; Total lung capacity, % of predicted (TLC%): 62.2% ± 11.8 vs. 68.6% ± 11.3%, p < 0.001) were significantly different at presentation between males and females, respectively. Comorbidities such as coronary artery disease (OR: 3.5-95% CI: 1.6-7.6) and other cardiovascular diseases (including atrial fibrillation and heart failure) (OR: 3.8-95% CI: 1.9-7.8) also showed significant differences between the genders. The K- BILD showed poor quality of life, but no difference was found between genders in total score (54 ± 11 vs. 54 ± 10, p = 0.61 in males vs. females, respectively).

conclusionsThis study shows that female patients with IPF have a more preserved lung function than males at inclusion, while males have a significant burden of cardiovascular comorbidities. However, QoL and results on the 6MWT did not differ between the groups. These gender differences may be of importance both at diagnosis and follow- up of patients with IPF.

Indexed as

Quality of LifeSex FactorsAgedAged, 80 and overCohort StudiesComorbidityCross-Sectional StudiesFemaleHumansIdiopathic Pulmonary FibrosisLungMaleMiddle AgedMultivariate AnalysisRegistriesRegression AnalysisComorbiditiesGender perspectiveIdiopathic pulmonary fibrosisInterstitial lung diseaseKBILDRegistry

Identifiers

PMID31771560
PMCPMC6880431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.